EXPE’s Uniform Adjusted EPS’ is substantially greater than as-reported earnings suggest and expected to grow materially, implying valuations may be too cheap

August 16, 2017

  • EXPE’s profitability is materially distorted by accounting for R&D and stock option expense
  • As such, their UAFRS EPS’ reached $1.25 in Q2, and $4.62 over the last four quarters, well above traditional EPS of $0.36 in Q2 and $2.11 over the past year
  • At current valuations, markets are embedding expectations for 2% EPS’ growth annually, which is substantially lower than analyst projections for almost 10% annual EPS’ growth, warranting material equity upside should the firm meet estimates


Expedia, Inc. (EXPE) released Q2 2017 earnings on 7/27, beating on the top and bottom line, but after opening higher the following day, shares fell over 6% in the next several weeks, as investors took profits on what initially appears like an expensive name. EPS came in at $0.36 for the quarter, and non-GAAP EPS came in at $0.89, beating by $0.53, and revenues beat by $50m. While shares rallied early the day after the firm announced the beat, this was short lived, as investors have grown worried about what appear to be historically high valuations.

However, after making appropriate adjustments under Uniform Adjusted Financial Reporting Standards (UAFRS), it is apparent that earnings are actually far stronger than as-reported EPS suggests, and valuations are actually rather cheap, supporting higher prices, and suggesting the post-earnings decline in EXPE’s stock price was unwarranted.

Specifically, under UAFRS, Uniform EPS (EPS’) actually reached $1.25 in Q2, over 3x GAAP EPS, and over the last four quarters has been $4.62, more than 2x as-reported EPS of $2.11 in the same timeframe.  This indicates that valuations are not nearly as high as traditional P/E would suggest, and instead of taking profits near perceived highs, investors should consider EXPE a value stock with serious growth potential that would warrant material equity upside.

The quarterly results show a similar trend, with EPS’ expected to remain positive, and well above as-reported EPS going forward, as it has in each of the last three quarters, and, should EPS’ continue to grow as it is expected to, this suggests valuations may be too cheap.

UAFRS, Uniform Adjusted Financial Reporting Standards, call for removal of distortions from issues like the treatment of R&D and stock option expense. Once removed, it is apparent that EXPE’s profitability is far greater than as-reported metrics suggest, indicating that the firm is actually substantially cheaper than as-reported valuations would lead investors to believe. This suggests that the post-earnings decline in EXPE’s stock price was unwarranted.

UAFRS vs. As-Reported EPS

Investors make major decisions about which companies to own based on quarterly company earnings, the most common metric mentioned in traditional corporate investment analysis.

However, more often than not, the earnings that companies report in any given quarter can swing wildly and lead investors to completely wrong conclusions, because GAAP and IFRS rules force management to report results in ways that are not representative of the real operating performance of the business.

While there is a case to be made that some management teams can use “creative accounting” to adjust numbers, the research would show that more often than not, the real problem is with the accounting rules themselves, not management’s use of them.

The UAFRS Advisory Council has identified over 130 accounting and financial reporting inconsistencies (some of which can be found here), of which several have material impact on EXPE’s financials.

Impact of Adjustments from GAAP to UAFRS

Two key UAFRS adjustments have the largest impact on EXPE’s income statement, to get from earnings to UAFRS-adjusted earnings. These are related to R&D and stock option expense.

GAAP and to a lesser extent IFRS (which allows for capitalization of a portion of R&D expense) treat R&D investments as expenses, when in actuality these are investments in a company’s future operations. They may be good investments or bad investments, but it’s hard to think of R&D as cost of goods sold.

In the case of R&D expense, this is often a multi-year investment in a firm’s future offerings.  Expensing R&D violates the basic matching rule of accounting, that expenses should be recognized in the period the related revenue is recognized.

Expensing R&D can also dramatically increase earnings volatility, as the timing of R&D related to multi-year projects can create lumpy earnings volatility, distorting understanding of a company’s real profitability.

Additionally, EXPE has had material non-cash stock option expense since the company was founded. This is treated as an expense to the company in accounting statements, when it is actually a way for the company to give employees an ownership stake in the company. As such, this non-cash expense should be treated as dilution to equity holders and another claim against the Enterprise Value of the firm, as opposed to it being treated as an annual expense. This is especially true as, unless the company uses cash to buy shares (to suppress dilution for equity holders from the option grants being exercised), there is no cash impact on the company.

UAFRS-reporting adjusts for these traditional accounting distortions by treating all R&D as investing cash flows and re-bucketing stock option expense into enterprise value. These simple reclassifications remove a tremendous amount of accounting noise related to investment activities and improves investors understanding of the operating earnings of a business.

Greater-than-reported EPS’ and expectations for growth suggest valuations may be too cheap

At current prices, EXPE is trading at a 25.5x traditional forward P/E, which, when compared to the firm’s largest competitor, PCLN, appears fairly expensive, and may indicate an overvalued firm.

However, after making the requisite adjustments, it is apparent that the firm is actually trading at a UAFRS-based P/E of 13.5x, which is below corporate averages, and well below that of its main competitor, PCLN.

Specifically, when considering the fact that EPS’ is expected to grow considerably going forward, valuations below corporate averages are unwarranted. At a 13.5x UAFRS-based P/E, markets are embedding expectations for annual EPS’ growth of just 2%, which is markedly lower than long-term analyst estimates for almost 10% annual EPS’ growth. As such, should EXPE simply maintain growth in-line with analyst estimates, material multiple expansion and equity upside would be warranted.

By using Uniform Adjusted Financial Reporting Standards (UAFRS), investors see a cleaner picture that distorted GAAP and IFRS metrics cannot show. By standardizing financial reporting consistently across time and across companies, corporate performance and valuation metrics improve dramatically. Comparability of a company’s earnings over time, trends in corporate profitability and comparability in earnings power and earnings growth across close competitors and different sectors becomes far more relevant and reliable.

To find out more about Expedia, Inc. and how their performance and market expectations compare to peers, click here to access the open beta of the Valens Research database.

Our Chief Investment Strategist, Joel Litman, chairs the Valens Research Committee, which is responsible for this article. Professor Litman is regarded globally for his expertise in financial statement analysis, fundamental research, and particularly Uniform Accounting, UAFRS.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683